Effects of Growth Hormone–Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults: Results of a Controlled Trial

Falutz J. et al.

The pivotal trial that got tesamorelin to FDA approval for HIV-associated visceral adiposity. 15% reduction in VAT area over 26 weeks with no change in subcutaneous fat or BMI, and IGF-1 into the upper-normal range. Still the cleanest modern GHRH-analog dataset in adults.

Nass R. et al.

The single best human MK-677 trial. Two years in healthy older adults: +1.1 kg fat-free mass, no improvement in strength or function, fasting glucose up, insulin sensitivity down. Restores GH to young-adult levels — without proving that doing so does anything useful.

Teichman S.L. et al.

The canonical first-in-human dataset for CJC-1295 with DAC: 2- to 10-fold GH elevation lasting six-plus days and IGF-1 elevation lasting nine to eleven days from a single injection. Everything written about CJC-1295 traces back here. Phase-2 development never continued — note that.

Raun K. et al.

The Novo Nordisk paper that introduced ipamorelin as the first GH-releasing peptide that doesn't drag cortisol and prolactin along with it. Foundational pharmacology — the reason ipamorelin gets paired with CJC-1295 in every modern protocol.